Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BIOMERICA INC (BMRA)

Biomerica sells 6% Diagnosis S.A. stake to CEO-affiliated buyers for $500,000

Neutral Impact 3 of 5 m&a Written later

Biomerica agreed on May 29, 2026 to sell 78,750 shares of Diagnosis S.A., about 6% of that Polish company, for $500,000 to buyers affiliated with CEO Zackary Irani. The buyers paid upfront in exchange for a secured 12-month note at 8% interest, pending transfer of the shares, which is expected to close within thirty days subject to Polish regulatory approvals.

Key points

  • Shares sold: 78,750 shares of Diagnosis S.A., about 6% of issued and outstanding shares
  • Purchase price: $500,000, paid by buyers in exchange for a secured promissory note
  • Note terms: 8% annual interest, matures 12 months from May 29, 2026, secured by a lien on the shares
  • Closing conditions, including Polish regulatory approvals, expected to be met within thirty days of May 29, 2026

The filing

CompanyBIOMERICA INC (BMRA)
Form8-K, current report
Filed with the SECJun 4, 2026, 4:45 PM ET
Accession number0001493152-26-027290

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.